WallStreetZenWallStreetZen

NASDAQ: SUPN
Supernus Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for SUPN

Based on 5 analysts offering 12 month price targets for Supernus Pharmaceuticals Inc

Min Forecast
$55.00+12.06%
Avg Forecast
$61.60+25.51%
Max Forecast
$65.00+32.44%

Should I buy or sell SUPN stock?

Based on 5 analysts offering ratings for Supernus Pharmaceuticals Inc.

Strong Buy
Strong Buy
4 analysts 80%
Buy
0 analysts 0%
Hold
1 analysts 20%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model "Buy" agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their SUPN stock forecasts and price targets.

SUPN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-12-19
lockedlocked$00.00+00.00%2025-10-29
lockedlocked$00.00+00.00%2025-10-23
lockedlocked$00.00+00.00%2025-10-09Find Out Why
lockedlocked$00.00+00.00%2025-09-30

1 of 1

Forecast return on equity

Is SUPN forecast to generate an efficient return?

Company
39.31%
Industry
35.36%
Market
216.29%
SUPN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SUPN forecast to generate an efficient return on assets?

Company
29.06%
Industry
19.03%
SUPN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SUPN earnings per share forecast

What is SUPN's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$3.68
Avg 2 year Forecast
$4.53
Avg 3 year Forecast
$6.27

SUPN revenue forecast

What is SUPN's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$874.6M+28.33%
Avg 2 year Forecast
$1.0B+50.69%
Avg 3 year Forecast
$1.2B+73.28%
SUPN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SUPN revenue growth forecast

How is SUPN forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
20.1%
Industry
36.02%
Market
22.81%
SUPN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SUPN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SUPN vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
SUPN$49.08$61.60+25.51%Strong Buy
HCM$14.78$13.75-6.97%Strong Sell
PBH$67.03$75.33+12.39%Buy
AVDL$21.57$20.20-6.35%Hold
BHC$5.66$8.00+41.34%Hold
View Top Pharmaceutical Stocks

Supernus Pharmaceuticals Stock Forecast FAQ

Is Supernus Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: SUPN) stock is to Strong Buy SUPN stock.

Out of 5 analysts, 4 (80%) are recommending SUPN as a Strong Buy, 0 (0%) are recommending SUPN as a Buy, 1 (20%) are recommending SUPN as a Hold, 0 (0%) are recommending SUPN as a Sell, and 0 (0%) are recommending SUPN as a Strong Sell.

If you're new to stock investing, here's how to buy Supernus Pharmaceuticals stock.

What is SUPN's earnings growth forecast for 2026-2028?

(NASDAQ: SUPN) Supernus Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 51.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.92%.

Supernus Pharmaceuticals's earnings in 2026 is -$19,117,000.On average, 8 Wall Street analysts forecast SUPN's earnings for 2026 to be $210,940,001, with the lowest SUPN earnings forecast at $125,871,341, and the highest SUPN earnings forecast at $351,002,831. On average, 7 Wall Street analysts forecast SUPN's earnings for 2027 to be $259,970,879, with the lowest SUPN earnings forecast at $238,818,393, and the highest SUPN earnings forecast at $279,357,313.

In 2028, SUPN is forecast to generate $359,689,743 in earnings, with the lowest earnings forecast at $328,726,494 and the highest earnings forecast at $388,330,748.

What is SUPN's revenue growth forecast for 2026-2028?

(NASDAQ: SUPN) Supernus Pharmaceuticals's forecast annual revenue growth rate of 20.1% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 36.02%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.81%.

Supernus Pharmaceuticals's revenue in 2026 is $681,539,000.On average, 8 Wall Street analysts forecast SUPN's revenue for 2026 to be $50,148,422,117, with the lowest SUPN revenue forecast at $46,830,767,326, and the highest SUPN revenue forecast at $52,379,496,225. On average, 7 Wall Street analysts forecast SUPN's revenue for 2027 to be $58,887,512,450, with the lowest SUPN revenue forecast at $54,472,955,894, and the highest SUPN revenue forecast at $65,768,234,450.

In 2028, SUPN is forecast to generate $67,717,772,350 in revenue, with the lowest revenue forecast at $62,385,212,800 and the highest revenue forecast at $74,541,155,000.

What is SUPN's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: SUPN) forecast ROA is 29.06%, which is higher than the forecast US Drug Manufacturers - Specialty & Generic industry average of 19.03%.

What is SUPN's Price Target?

According to 5 Wall Street analysts that have issued a 1 year SUPN price target, the average SUPN price target is $61.60, with the highest SUPN stock price forecast at $65.00 and the lowest SUPN stock price forecast at $55.00.

On average, Wall Street analysts predict that Supernus Pharmaceuticals's share price could reach $61.60 by Dec 19, 2026. The average Supernus Pharmaceuticals stock price prediction forecasts a potential upside of 25.51% from the current SUPN share price of $49.08.

What is SUPN's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: SUPN) Supernus Pharmaceuticals's current Earnings Per Share (EPS) is -$0.33. On average, analysts forecast that SUPN's EPS will be $3.68 for 2026, with the lowest EPS forecast at $2.20, and the highest EPS forecast at $6.12. On average, analysts forecast that SUPN's EPS will be $4.53 for 2027, with the lowest EPS forecast at $4.17, and the highest EPS forecast at $4.87. In 2028, SUPN's EPS is forecast to hit $6.27 (min: $5.73, max: $6.77).

What is SUPN's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: SUPN) forecast ROE is 39.31%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.